Abp 234 vs MB12

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Abp 234

Developed by Amgen

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06430866 (registry estimate)

No aligned efficacy figure on record for this race.

MB12

Developed by Laboratorio Elea Phoenix S.A. and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT05668650 · Phase 3 · status unknown

This is a randomized, double-blind, active-controlled trial with over 170 patients, but its primary comparison is a pharmacokinetic equivalence check between MB12 and the reference drug rather than a clinical efficacy comparison. No results have been posted yet.

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAbp 234MB12
PFS, median—Trial running · NCT06430866—Trial running · NCT06687369
OS, median—Trial running · NCT06430866—Trial running · NCT06687369
ORR—Trial running · NCT06430866—Trial running · NCT06687369
Duration of response, median—Trial running · NCT06430866—Trial running · NCT06687369

PFS, median

Abp 234
—Trial running · NCT06430866
MB12
—Trial running · NCT06687369

OS, median

Abp 234
—Trial running · NCT06430866
MB12
—Trial running · NCT06687369

ORR

Abp 234
—Trial running · NCT06430866
MB12
—Trial running · NCT06687369

Duration of response, median

Abp 234
—Trial running · NCT06430866
MB12
—Trial running · NCT06687369
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Abp 234: no structured comparison results are available for Non-Small Cell Lung Cancer.

MB12: no structured comparison results are available for Non-Small Cell Lung Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abp 234's landscape · MB12's landscape